Información del artículo
El Texto completo está disponible en PDF
Referencias bibliográficas
[1.]
Goldhirsch A., Gelber R.D..
Endocrine therapies of breast cancer.
Semin Oncol, 4 (1996), pp. 494-505
[2.]
Consensus Conference.
Adjuvant chemotherapy for breast cancer.
JAMA, 254 (1985), pp. 3461-3463
[3.]
NHI Consensus Conference.
Treatment of early-stage breast cancer.
JAMA, 265 (1991), pp. 391-395
[4.]
Gilck J.H..
Meeting Highlights: Adjuvant therapy for breast cancer.
J Natl Cancer Inst, 84 (1992), pp. 1479-1485
[5.]
Glick J.H., Gelber R.D., Goldhrirsch A., Senn H.J..
Adjuvant therapy of primary breast cancer: 4th International Conference on Adjuvant Therapy of Primary Breast Cancer.
St. Gallen Switzerland. Ann Oncol, 3 (1992), pp. 801-807
[6.]
Goldhrirsch A., Wood W.C., Senn H-J, Glick J.H., Gelber R.D..
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.
J Natl Cancer Inst, 87 (1995), pp. 1441-1445
[7.]
Goldhrirsch A., Glick J.H., Gelber R.D., Senn H-J.
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.
J Natl Cancer Inst, 90 (1998), pp. 1601-1608
[8.]
Elleedge R.M., Green S., Ciocca R.D., Pugh R., Allred D.C., Clark G.M., et al.
HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: a Southwest Oncology Group Study.
Clin Cancer Res, 4 (1998), pp. 7-12
[9.]
Poon D.H., Chui Y.C., McCague R., Llnning P.E., Feng R., Rowlands M.G., Jarman M..
Analysis of phase I and phase II metabolites of tamoxifen in breast cancer patients.
Drug Metab Dispos, 21 (1993), pp. 1119-1124
[10.]
Early Breast Cancer Trialist Collaborative Group.
Tamoxifen for early breast cancer: an overview of the randomised trials.
Lancet, 351 (1998), pp. 1451-1467
[11.]
Fisher B., Costantino J.P., Wickerham D.L., Redmond C.K., Kavanah M., Cronin W.M., et al.
Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Projet P-1 study.
J Natl Cancer Inst, 90 (1998), pp. 1371-1388
[12.]
Chen Y., Thompson W., Semenciw R., Mao Y..
Epidemiology of contralateral breast cancer.
Cancer Epidemiol Biomarkers Prev, 8 (1999), pp. 855-861
[13.]
Early Breast cancer Ttrialists' Collaborative Group.
Ovarian ablation in early breast cancer: overview of the randomised trials.
Lancet, 348 (1996), pp. 1189-1196
[14.]
Filipponi P., Cristallini S., Rizzello E., Policani G., Fedeli L., Gregorio F., et al.
Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial.
Bone, 18 (1996), pp. 179-184
[15.]
Hortobagyi G.N..
Treatment of breast cancer.
N Engl J Med, 339 (1998), pp. 974-984
[16.]
Kimmick G., Muss H.B..
Current status of endocrine therapy for metastatic breast cancer.
Oncology, 9 (1995), pp. 877-890
[17.]
Stuart N.S., Warwick J., Blackledge G.R., Spooner D., Keen C., Taylor A.R., et al.
A randomiced phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer.
Eur J Cancer, 32 (1996), pp. 1888-1892
[18.]
Hayes D.F., Van Zyl J.A., Hacking A., Goelhals L., Bezwoda W.R., Mailliard J.A., et al.
Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer.
J Clin Oncol, 13 (1995), pp. 2556-2566
[19.]
Crump M., Sawka C.A., DeBoer G., Buchanan R.B., Ingle J.N., Forbes J., et al.
An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer.
Breast Cancer Res Treat, 44 (1997), pp. 201-210
[20.]
Buzdar A.U., Plourde P.V., Hortobagyi G.N..
Aromatase inhibitors in metastatic breast cancer.
Semin Oncol, 23 (1996), pp. 28-32
[21.]
Buzdar A.U., Smith R., Vogal C., Bonomi P., Keller A.M., Favis G., et al.
Fadrozole HCL (CGS-16949 A) versus megestrol acetate in postmeno-pausal patients with metastatic breast carcinoma: results of two randomized double blind controlled multi-institutional trials.
Cancer, 77 (1996), pp. 2503-2513
Copyright © 2000. Academia de Ciencias Médicas de Bilbao